JP7135068B2 - Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ - Google Patents
Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ Download PDFInfo
- Publication number
- JP7135068B2 JP7135068B2 JP2020508540A JP2020508540A JP7135068B2 JP 7135068 B2 JP7135068 B2 JP 7135068B2 JP 2020508540 A JP2020508540 A JP 2020508540A JP 2020508540 A JP2020508540 A JP 2020508540A JP 7135068 B2 JP7135068 B2 JP 7135068B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- osimertinib
- amino acid
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title claims description 10
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title claims 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title claims 2
- 229940121647 egfr inhibitor Drugs 0.000 title description 12
- 229960003278 osimertinib Drugs 0.000 claims description 68
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 45
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 45
- 102200048955 rs121434569 Human genes 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 38
- 230000001394 metastastic effect Effects 0.000 claims description 37
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 210000003169 central nervous system Anatomy 0.000 claims description 29
- 230000035772 mutation Effects 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 9
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 5
- 229960002584 gefitinib Drugs 0.000 claims description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229960001638 osimertinib mesylate Drugs 0.000 claims description 2
- FUKSNUHSJBTCFJ-UHFFFAOYSA-N osimertinib mesylate Chemical compound CS(O)(=O)=O.COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 FUKSNUHSJBTCFJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 57
- 238000011282 treatment Methods 0.000 description 44
- 229960002633 ramucirumab Drugs 0.000 description 43
- 241000282414 Homo sapiens Species 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 102000001301 EGF receptor Human genes 0.000 description 21
- 108060006698 EGF receptor Proteins 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 9
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 9
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 101150039808 Egfr gene Proteins 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 208000002667 Subdural Hematoma Diseases 0.000 description 3
- 206010042364 Subdural haemorrhage Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000010271 Heart Block Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001269 cardiogenic effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 102000055590 human KDR Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940092700 osimertinib 80 mg Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000007879 vasectomy Methods 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010036653 Presyncope Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037765 Radiation pneumonitis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010062546 Thrombosis in device Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007453 hemicolectomy Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- -1 poly(polyethylene) Polymers 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004353 relayed correlation spectroscopy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 201000002932 second-degree atrioventricular block Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000009612 semen analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022109875A JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548069P | 2017-08-21 | 2017-08-21 | |
| US62/548,069 | 2017-08-21 | ||
| US201862664529P | 2018-04-30 | 2018-04-30 | |
| US62/664,529 | 2018-04-30 | ||
| US201862672153P | 2018-05-16 | 2018-05-16 | |
| US62/672,153 | 2018-05-16 | ||
| PCT/US2018/047031 WO2019040348A1 (en) | 2017-08-21 | 2018-08-20 | COMBINATIONS OF EGFR INHIBITORS AND ANTI-VEGFR -2 HUMAN ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022109875A Division JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530851A JP2020530851A (ja) | 2020-10-29 |
| JP2020530851A5 JP2020530851A5 (enExample) | 2020-12-10 |
| JP7135068B2 true JP7135068B2 (ja) | 2022-09-12 |
Family
ID=63638326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508540A Active JP7135068B2 (ja) | 2017-08-21 | 2018-08-20 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
| JP2022109875A Withdrawn JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022109875A Withdrawn JP2022133436A (ja) | 2017-08-21 | 2022-07-07 | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11471457B2 (enExample) |
| EP (1) | EP3672633A1 (enExample) |
| JP (2) | JP7135068B2 (enExample) |
| WO (1) | WO2019040348A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022003286A2 (pt) * | 2019-08-23 | 2022-05-24 | Spectrum Pharmaceuticals Inc | Combinação de poziotinibe com inibidores de vegfr2 e métodos de uso da mesma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134242A1 (en) | 2014-03-04 | 2015-09-11 | Eli Lilly And Company | Anti-met in combination with anti-vegfr2 antibodies therapy for cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2362931T3 (es) | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| ES2791308T3 (es) | 2011-07-27 | 2020-11-03 | Astrazeneca Ab | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer |
-
2018
- 2018-08-20 US US16/633,230 patent/US11471457B2/en active Active
- 2018-08-20 EP EP18772972.8A patent/EP3672633A1/en active Pending
- 2018-08-20 WO PCT/US2018/047031 patent/WO2019040348A1/en not_active Ceased
- 2018-08-20 JP JP2020508540A patent/JP7135068B2/ja active Active
-
2022
- 2022-07-07 JP JP2022109875A patent/JP2022133436A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134242A1 (en) | 2014-03-04 | 2015-09-11 | Eli Lilly And Company | Anti-met in combination with anti-vegfr2 antibodies therapy for cancer |
Non-Patent Citations (1)
| Title |
|---|
| Therapeutic Advances in Respiratory Disease，2016年，Vol.10, No.6，p.549-565 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200155551A1 (en) | 2020-05-21 |
| US11471457B2 (en) | 2022-10-18 |
| WO2019040348A1 (en) | 2019-02-28 |
| JP2022133436A (ja) | 2022-09-13 |
| JP2020530851A (ja) | 2020-10-29 |
| EP3672633A1 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3031468T3 (en) | Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| RU2677245C2 (ru) | Комплексная терапия | |
| CN107614011A (zh) | Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗 | |
| JP2024112968A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン | |
| CN107921108A (zh) | 用于治疗癌症的hdac抑制剂和抗‑pd‑l1抗体的组合 | |
| JP2022133436A (ja) | Ｅｇｆｒ阻害剤と抗ヒトｖｅｇｆｒ－２抗体との組み合わせ | |
| AU2025252564A1 (en) | Combination treatments for melanoma | |
| KR20230047359A (ko) | 트라스투주맙, 탁산 및 vegfr-2 길항제와 병용하여 투카티닙을 이용하는 her2 양성 암의 치료 방법 | |
| TWI569808B (zh) | 肝細胞腫瘤（ｈｃｃ）之治療 | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| CN112915203A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| CN113117072A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| JP7574079B2 (ja) | 小児患者における癌の治療のためのラムシルマブ | |
| JP2019513767A (ja) | マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法 | |
| TW202541838A (zh) | 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途 | |
| WO2024155790A2 (en) | Novel approach for treatment of cancer using immunomodulation | |
| WO2023136837A1 (en) | Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc) | |
| WO2025122791A1 (en) | Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma | |
| WO2024100663A1 (en) | Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities | |
| CN117460534A (zh) | 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法 | |
| CA2980297C (en) | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer | |
| WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
| WO2021143671A1 (zh) | 抗pd-1抗体和喹唑啉衍生物的药物组合以及其用途、使用其的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210430 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220707 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220707 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220713 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220831 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7135068 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |